Highlights
About
Deep-lung Inhalation Therapies for Infectious Diseases
Corolabs develops a combination of inhaled medications together with a novel delivery system capable of reaching the deep lung.
The company’s aerosol technology is used to produce and deliver sub-micron droplets to the alveoli of the lung, enabling localized treatment of lower respiratory diseases as well as systemic drug delivery. This novel technology allows home-based treatments of lower respiratory diseases, traditionally treated only in hospital settings by intramuscular injection or intravenous therapy.
Additional advantages of targeted drug delivery to the deep lung include potential rapid onset of action as well as the opportunity for dose sparing and reduced side effects of systemically available drugs.
Corolabs was established shortly after the onset of the COVID-19 outbreak in Israel, after it became evident that COVID-19 mortality occurs as a result of deep-lung infections triggered by the coronavirus.
Corolabs is a subsidiary of Omega Life Science.
Identity
| Name | Corolabs |
|---|---|
| Slug | corolabs-ltd |
| Former names | Pulmogen |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OuEwuAKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Dec 2024 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Migdal HaEmek |
| HQ address | HaTa'asiya Street 5, Migdal HaEmek, Israel |
Classifications
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}